Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,863.00
Bid: 4,843.00
Ask: 4,847.00
Change: 32.00 (0.66%)
Spread: 4.00 (0.083%)
Open: 4,857.00
High: 4,932.00
Low: 4,837.00
Prev. Close: 4,831.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Third Quarter Trading Update

9 Oct 2023 07:00

RNS Number : 0520P
Croda International PLC
09 October 2023

9 October 2023

Croda International Plc

Third Quarter Trading Update

Croda International Plc ('Croda' or 'the Group') today provides an update on trading from 1 July to 30 September 2023 ('the third quarter' or 'the period').

Customers have continued to reduce their ingredient inventories in consumer care, crop and industrial end markets, due to a combination of destocking and a weaker demand environment. This has continued to depress sales volumes and our overall performance for the period was therefore weaker than originally anticipated.

In Consumer Care, sales volumes in the Beauty Care business were lower than expected in July and August with North America not recovering from quarter two. Beauty Care sales volumes have however improved in September and we expect the recovery to continue through the remainder of the year, albeit now from a lower base. Second half operating profit margin is expected to be lower than the first half year due to the negative leverage impact of low volumes and adverse business mix. Customer appetite for innovation remains high, with continued demand for ingredients differentiated by sustainability. F&F sales remain strong, Home Care sales are improving sequentially, and positive price/mix continues to offset low volumes in Beauty Actives.

In Life Sciences, sales have weakened further in Crop Protection and improvement is now expected to commence in the first half of next year. Seed Enhancement continues to perform well with incremental future opportunities being driven by regulatory change. The Pharma business continues to make exciting progress with its industry-leading position in biologics delivery and recent partnerships helping to further strengthen its pipeline of opportunities. We expect shipments of lipid systems to our principal Covid-19 vaccine customers to occur as planned and non-Covid sales to remain resilient as customer innovation pipelines continue to develop.

Industrial Specialties continues to be adversely affected by weak industrial demand globally and is not expected to be profitable in the second half of the year.

With no indications of a significant rebound to come in the fourth quarter, Croda now expects full year 2023 Group adjusted profit before tax to be between £300m and £320m (previously £370m-£400m).

Several cost measures have been implemented since June this year to protect profitability. Actions include tighter budgetary control of fixed costs and optimising production through plant shutdowns and reduced shift patterns, at the same time as increasing sales activity to meet ongoing customer demand for innovation. We are also seeking efficiency savings from simplifying business processes and ways of working. Croda remains well positioned to rebound when the macro environment improves.

Capital discipline is being maintained by managing down inventory and challenging non-committed, non-safety-critical capex projects, whilst striking a balance with continuing to invest in future growth.

Croda will report full year results for the year ending 31 December 2023 on 27 February 2024.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014 (as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018). The Market Abuse Regulation requires us to state the person responsible for making this announcement who is Steve Foots, Chief Executive Officer.

Conference call:

There will be a conference call for covering analysts at 0800 BST this morning with dial-in details below. Participants are encouraged to dial in early as they will need to register with the operator.

· Operator assisted dial-in: +44 (0)33 0551 0200; passcode "Croda"

For enquiries contact:

Investors: David Bishop, Croda +44 7823 874428

Press: Charlie Armitstead, Teneo +44 7703 330269

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTZZMGGLRGGFZM
Date   Source Headline
7th Oct 20227:00 amRNSInvestor seminar
5th Oct 20224:42 pmRNSDirector/PDMR Shareholding
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion
29th Mar 20227:00 amRNSInvestor seminar
22nd Mar 20226:14 pmRNSAnnual Financial Report
22nd Mar 20224:49 pmRNSDirector/PDMR Shareholding
16th Mar 20225:21 pmRNSDirector/PDMR Shareholding
16th Mar 20225:20 pmRNSDirector/PDMR Shareholding
16th Mar 20225:19 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:13 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:04 pmRNSDirector/PDMR Shareholding
16th Mar 20225:03 pmRNSDirector/PDMR Shareholding
15th Mar 202211:24 amRNSDirector/PDMR Shareholding
11th Mar 20222:25 pmRNSDirector/PDMR Shareholding
10th Mar 20221:10 pmRNSDirector/PDMR Shareholding
3rd Mar 202211:27 amRNSDirector/PDMR Shareholding
1st Mar 20227:00 amRNSResults for the year ended 31 December 2021
11th Feb 20222:26 pmRNSDirector/PDMR Shareholding
25th Jan 202210:47 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.